Skip to main content
Erschienen in: Annals of Hematology 9/2016

04.07.2016 | Original Article

Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma

verfasst von: Saad Akhtar, Shahzad M. Rauf, Tusneem A. M. Elhassan, Irfan Maghfoor

Erschienen in: Annals of Hematology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

High-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) can salvage many patients with relapsed or refractory Hodgkin’s lymphoma (HL). We are reporting the outcome of HDC auto-SCT and the impact of 21 prognostic factors in relapsed and refractory adolescent (14–21 years) and young adult (>21–30 years) (AYA) HL patients. We used Fine and Gray’s competing risk analysis method and regression model for outcome analysis. From 1996 to 2013, 290 consecutive patients with biopsy-proven HL underwent HDC auto-SCT for relapsed/refractory HL; 216 patients (74.5 %) were AYA at the time of auto-SCT. Male/female were equal, median age at auto-SCT was 22.4 years, and there were 94 adolescent (43.5 %) and 122 young adults (56.5 %). There was refractory disease in 121 (56 %) patients, relapsed in 95 (44 %). Median follow-up was 72.6 months. The Kaplan-Meier method estimated that 5-year overall survival is 62.7 % (adolescents (63.5 %), young adults (62 %)) and event-free survival was 51.3 %. Five-year cumulative incidence of disease-specific death (DS-death) is 33 % and that of DS-event is 45 %. For DS-death, the multivariate analysis identified complete remission (CR) duration of <12 months (hazard ratio (HR) 3.61, P = 0.0009), no CR after salvage (HR: 3.93, P = 0.0002), and nodular sclerosis pathology (HR 3.3, P = 0.016) and positive B symptoms (HR 2, P = 0.028) as negative factors. For DS-event, CR duration of <12 months (HR 1.88, P = 0.02), no CR after salvage (HR 3.47, P = 0.000005) and nodular sclerosis pathology (HR 1.88, P = 0.02) were found significant. The Kaplan-Meier method estimated overall survival (OS) at 36 months with 0–2:3:4 factors being 93.6:54:21 %, respectively (P value <0.001). Kaplan-Meier estimated event-free survival (EFS) at 36 months with 0–1:2:3 factors being 84.6:65:31 %, respectively (P value <0.001). Clinically, adolescents have similar outcomes as young adults.
Literatur
1.
Zurück zum Zitat Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071CrossRefPubMed Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071CrossRefPubMed
2.
Zurück zum Zitat Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relpased and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054CrossRefPubMed Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relpased and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054CrossRefPubMed
3.
Zurück zum Zitat Bonfante V, Santoro A, Viviani S et al (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528–534PubMed Bonfante V, Santoro A, Viviani S et al (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528–534PubMed
4.
Zurück zum Zitat Longo DL, Duffey PL, Young RC et al (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218PubMed Longo DL, Duffey PL, Young RC et al (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218PubMed
5.
Zurück zum Zitat Reece DE, Barnett MJ, Shepherd JD et al (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451–456PubMed Reece DE, Barnett MJ, Shepherd JD et al (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451–456PubMed
6.
Zurück zum Zitat Horning SJ, Chao NJ, Negrin RS et al (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–813PubMed Horning SJ, Chao NJ, Negrin RS et al (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–813PubMed
7.
Zurück zum Zitat Lazarus HM, Rowlings PA, Zhang MJ et al (1999) Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534–545PubMed Lazarus HM, Rowlings PA, Zhang MJ et al (1999) Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534–545PubMed
8.
Zurück zum Zitat André M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. J Clin Oncol 17:222–229PubMed André M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. J Clin Oncol 17:222–229PubMed
9.
Zurück zum Zitat Akhtar S, El Weshi A, Abdelsalam M, Hussaini HJI, Rahal M, Maghfoor I (2007) Primary refractory Hodgkin’s lymphoma: out come after high dose chemotherapy and autologous stem cell transplantation and impact of various prognostic factors on overall and event free survival. A single institution result of 66 patients. Bone Marrow Transplant 40:651–658CrossRefPubMed Akhtar S, El Weshi A, Abdelsalam M, Hussaini HJI, Rahal M, Maghfoor I (2007) Primary refractory Hodgkin’s lymphoma: out come after high dose chemotherapy and autologous stem cell transplantation and impact of various prognostic factors on overall and event free survival. A single institution result of 66 patients. Bone Marrow Transplant 40:651–658CrossRefPubMed
10.
Zurück zum Zitat Josting A, Rueffer U, Franklin J et al (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96:1280–1286PubMed Josting A, Rueffer U, Franklin J et al (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96:1280–1286PubMed
11.
Zurück zum Zitat Satwani P, Ahn KW, Carreras J et al (2015) A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 50:1416–1423CrossRefPubMedPubMedCentral Satwani P, Ahn KW, Carreras J et al (2015) A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 50:1416–1423CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Shankar A, Hayward J, Kirkwood A et al (2014) Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma—results of the UK HD3 relapse treatment strategy. Br J Haematol 165:534–544CrossRefPubMed Shankar A, Hayward J, Kirkwood A et al (2014) Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma—results of the UK HD3 relapse treatment strategy. Br J Haematol 165:534–544CrossRefPubMed
13.
Zurück zum Zitat Gorde-Grosjean S, Oberlin O, Leblanc T et al (2012) Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 158:649–656CrossRefPubMed Gorde-Grosjean S, Oberlin O, Leblanc T et al (2012) Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 158:649–656CrossRefPubMed
14.
Zurück zum Zitat Harris RE, Termuhlen AM, Smith LM et al (2011) Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant 17:249–258CrossRefPubMed Harris RE, Termuhlen AM, Smith LM et al (2011) Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant 17:249–258CrossRefPubMed
15.
Zurück zum Zitat Shafer JA, Heslop HE, Brenner MK et al (2010) Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma 51:664–670CrossRefPubMedPubMedCentral Shafer JA, Heslop HE, Brenner MK et al (2010) Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma 51:664–670CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Schellong G, Dörffel W, Claviez A et al (2005) Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group J. Clin Oncol 23:6181–6189CrossRef Schellong G, Dörffel W, Claviez A et al (2005) Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group J. Clin Oncol 23:6181–6189CrossRef
17.
Zurück zum Zitat Prete A, Bonetti F, Rondelli R et al (2005) High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin’s disease (HD): results and outcome. ASH Annual Meeting Abstracts 106:2088 Prete A, Bonetti F, Rondelli R et al (2005) High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin’s disease (HD): results and outcome. ASH Annual Meeting Abstracts 106:2088
18.
Zurück zum Zitat Lieskovsky YE, Donaldson SS, Torres MA et al (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol 22:4532–4540CrossRefPubMed Lieskovsky YE, Donaldson SS, Torres MA et al (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol 22:4532–4540CrossRefPubMed
19.
Zurück zum Zitat Claviez A, Canals C, Dierickx D et al (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 114:2060–2067CrossRefPubMed Claviez A, Canals C, Dierickx D et al (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 114:2060–2067CrossRefPubMed
20.
Zurück zum Zitat Stoneham S, Ashley S, Pinkerton CR et al (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26:740–745CrossRefPubMed Stoneham S, Ashley S, Pinkerton CR et al (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26:740–745CrossRefPubMed
21.
Zurück zum Zitat Frankovich J, Donaldson SS, Lee Y et al (2001) High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7:49–57CrossRefPubMed Frankovich J, Donaldson SS, Lee Y et al (2001) High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7:49–57CrossRefPubMed
22.
Zurück zum Zitat Verdeguer A, Pardo N, Madero L et al (2000) Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 25:31–34CrossRefPubMed Verdeguer A, Pardo N, Madero L et al (2000) Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 25:31–34CrossRefPubMed
23.
Zurück zum Zitat Baker KS, Gordon BG, Gross TG et al (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol 17:825–831PubMed Baker KS, Gordon BG, Gross TG et al (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol 17:825–831PubMed
24.
Zurück zum Zitat Rauf MS, Maghfoor I, Elhassan TA, Akhtar S (2015) High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin’s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Med Oncol 32:388CrossRefPubMed Rauf MS, Maghfoor I, Elhassan TA, Akhtar S (2015) High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin’s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Med Oncol 32:388CrossRefPubMed
25.
Zurück zum Zitat Akhtar S, Tbakhi A, Humaidan H et al (2006) ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin’s lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 37:277–282CrossRefPubMed Akhtar S, Tbakhi A, Humaidan H et al (2006) ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin’s lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 37:277–282CrossRefPubMed
26.
Zurück zum Zitat Akhtar S, Al-Sugair A, Abouzied M et al (2013) Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 48:1530–1536CrossRefPubMed Akhtar S, Al-Sugair A, Abouzied M et al (2013) Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 48:1530–1536CrossRefPubMed
27.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMed Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMed
28.
Zurück zum Zitat Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514CrossRefPubMed Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514CrossRefPubMed
29.
Zurück zum Zitat Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
30.
Zurück zum Zitat Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45:1388–1395CrossRefPubMed Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45:1388–1395CrossRefPubMed
31.
Zurück zum Zitat Rauf MS, Akhtar S, Maghfoor I (2015) Changing trends of adult lymphoma in the Kingdom of Saudi Arabia—comparison of data sources. Asian Pac J Cancer Prev 16:2069–2072CrossRefPubMed Rauf MS, Akhtar S, Maghfoor I (2015) Changing trends of adult lymphoma in the Kingdom of Saudi Arabia—comparison of data sources. Asian Pac J Cancer Prev 16:2069–2072CrossRefPubMed
32.
Zurück zum Zitat Akhtar S, Elhassan TA, Edesa W et al (2016) High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. Ann Hematol 95:49–54CrossRefPubMed Akhtar S, Elhassan TA, Edesa W et al (2016) High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. Ann Hematol 95:49–54CrossRefPubMed
33.
Zurück zum Zitat Daw S, Wynn R, Wallace H (2011) Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol 152:249–260CrossRefPubMed Daw S, Wynn R, Wallace H (2011) Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol 152:249–260CrossRefPubMed
34.
Zurück zum Zitat Smith SD, Moskowitz CH, Dean R et al (2011) Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 153:358–363CrossRefPubMed Smith SD, Moskowitz CH, Dean R et al (2011) Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 153:358–363CrossRefPubMed
Metadaten
Titel
Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma
verfasst von
Saad Akhtar
Shahzad M. Rauf
Tusneem A. M. Elhassan
Irfan Maghfoor
Publikationsdatum
04.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2016
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2736-5

Weitere Artikel der Ausgabe 9/2016

Annals of Hematology 9/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.